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We read with great interest the manuscript writ-
ten by Makiyama et al [1]. In this paper, the authors 
reported outcome results of the randomized phase 
II study WJOG7112G (T-ACT Study). The study 
compared the efficacy of single agent paclitaxel to 
paclitaxel plus the continuous administration of 
trastuzumab beyond progression in HER2-positive 
advanced gastric cancer patients who progressed 
following trastuzumab first-line standard chemo-
therapy. A total of 91 patients were randomized; of 
these, 46 received paclitaxel while, in contrast, 45 
received paclitaxel plus trastuzumab. The median 
progression-free survival (PFS) was 3.2 months in 
the paclitaxel arm and 3.7 months in the paclitaxel 
with trastuzumab, whereas the overall response rate 
(RR) was 32% in the paclitaxel arm and 33% in the 
paclitaxel with trastuzumab arm. Lastly, the median 
overall survival (OS) was 10 months for both arms. 
The authors concluded that the strategy of trastuzu-
mab beyond progression failed to improve PFS in 
patients diagnosed with HER2-positive advanced 
gastric cancer. 
To date, there is urgent need to identify the opti-
mal  second or further line of therapy for the treat-
ment of metastatic GC [2, 3] patients. Ramuciru-
mab is a monoclonal antibody against VEGFR2 [4] 
approved as the second or further line of treatment 
for the HER2-positive population. However, as dis-
cussed by the authors, a limited number of studies 
have described the efficacy of ramucirumab for this 
subgroup of patients so far. In 2019, De Vita et al. 
[5] evaluated the efficacy and safety of ramucirum-
ab plus paclitaxel in a small subgroup of 20 patients 
affected by gastric cancer from the RAINBOW trial 
who were previously administered with trastuzu-
mab. The authors observed a median PFS of 4.2 
months, a RR of 45.0% and a median OS of 11.4 
months (Tab. 1). Although a comparison between 
the studies is difficult due to the different clinical 
characteristics of evaluated patients and the source 
of the data (retrospective versus prospective), we 
must report a lower efficacy for the trastuzumab be-
yond progression strategy compared to “standard” 
second-line paclitaxel plus ramucirumab regimen. 
Moreover, a meta-analysis published in 2018 [6] 
showed that continuation of trastuzumab beyond 
first-line therapy added to second-line therapy did 
not prolong OS.
More recently, the antibody-drug conjugate 
named trastuzumab deruxtecan, consisting of tras-
tuzumab plus a cleavable tetrapeptide-based linker 
and a cytotoxic topoisomerase I inhibitor, showed 
significant improvements in terms of clinical re-
sponse and OS — compared with standard thera-
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pies — in patients with HER2-positive advanced 
GC who progressed while receiving at least two 
previous therapies, including trastuzumab [7].
Therefore, we strongly agree with the statement 
of the authors to compare future clinical trial of 
new anti-HER2 agents with paclitaxel plus ramu-
cirumab as the control arm. However, considering 
a potential crosstalk between HER-2 signalling and 
angiogenesis [8], we strongly encourage the pos-
sibility to perform future combination trials us-
ing anti-HER2 therapies plus ramucirumab-based 
regimens. 
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Table 1. Main outcomes in patients with Her2 positive gastric cancer treated with second line trastuzumab beyond 








t-ACt trastuzumab beyond progression + paclitaxel 45 33 3.7 10
rAiNBoW Paclitaxel + ramucirumab 20 45 4.2 11.4
oS — overall survival; PFS — progression-free survival
